zdorПроблемы здоровья и экологииHealth and Ecology Issues2220-09672708-6011Gomel State Medical University10.51523/2708-6011.2021-18-4-1zdor-2106Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESАктуальные аспекты вакцинопрофилактики COVID-19: широкие шаги из лаборатории в клиникуCurrent aspects of COVID-19 vaccine prophylaxis: big steps from laboratory to clinical practicehttps://orcid.org/0000-0002-1031-6506ГринькоД. В.GrinkoD. V.

Гринько Дмитрий Владимирович, директор

г. Минск

Dmitry V. Grinko, Director

Minsk

rceth@rceth.byhttps://orcid.org/0000-0002-1241-832XМоисеевД. В.MoiseevD. V.

Моисеев  Дмитрий  Владимирович,  д.ф.н., заведующий Республиканской контрольно-аналитической лабораторией

г. Минск

Dmitry V. Moiseev, PharmD, Head of the Republican Control and Analysis Laboratory

Minsk

rkal@rceth.byhttps://orcid.org/0000-0002-9435-6109ВоропаевЕ. В.VoropaevE. V.

Воропаев  Евгений  Викторович,  к.м.н., доцент, проректор по научной работе

г. Гомель

Evgenii V. Voropaev, PhD (Med), Associate Professor, Vice-Rector in charge of scientific work

Gomel 

voropaev.evgenii@gmail.comhttps://orcid.org/0000-0003-0483-7329СтомаИ. О.StomaI. O.

Стома Игорь Олегович, д.м.н., доцент, ректор

г. Гомель

Igor O. Stoma, DMedSc, Associate Professor, Rector

Gomel 

rektor@gsmu.byЦентр экспертиз и испытаний в здравоохраненииCenter for Examinations and Tests in Health ServiceГомельский государственный медицинский университетGomel State Medical University202130122021184516Copyright © Гринько Д.В., Моисеев Д.В., Воропаев Е.В., Стома И.О., 20212021Гринько Д.В., Моисеев Д.В., Воропаев Е.В., Стома И.О.Grinko D.V., Moiseev D.V., Voropaev E.V., Stoma I.O.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.gsmu.by/jour/article/view/2106

Более полутора лет мир переживает пандемию COVID-19. Коренным образом изменить ситуацию в борьбе с этой инфекцией возможно лишь при создании безопасных и эффективных вакцин. Всемирная организация здравоохранения (ВОЗ) и ее партнеры содействуют ускоренной разработке вакцин, поскольку именно вакцинация, наряду с социальным дистанцированием и использованием средств индивидуальной защиты, является эффективным способом профилактики коронавирусной инфекции. В данном обзоре освещены общие характеристики вакцин, зарегистрированных или одобренных как минимум одним национальным регулятором, риски и побочные эффекты вакцин, а также подходы к оценке эффективности вакцинации против COVID-19.

For more than a year and a half, the entire world has been experiencing the COVID-19 pandemic. Only the development of safe and effective vaccines may make the most significant changes in the fight against this infection. The World Health Organization (WHO) and its partners are contributing to accelerated development of vaccines because it is the vaccination along with social distancing and the use of personal protective equipment that is an effective way to prevent the coronavirus disease. This review covers general characteristics of vaccines registered or approved by at least one national regulator, the risks and side effects of the vaccines, as well as approaches to assess the effectiveness of COVID-19 vaccination.

вакцинацияCOVID-19SARS-CoV-2вакциныэффективностьпобочные эффектыклинические исследованияvaccinationCOVID-19SARS-CoV-2vaccineseffectivenessside effectsclinical trialsReferencesЕвразийская экономическая комиссия (ЕЭК) [Электронный ресурс]. [дата обращения 2021 сентябрь 13]. Режим доступа: https://eec.eaeunion.org/comission/about/The Eurasian Economic Commission (EEC) [Electronic resource]. [date of access 2021 September 13]. Available from: https://eec.eaeunion.org/comission/about/ (In Russ.).Министерство здравоохранения Республики Беларусь [Электронный ресурс]. [дата обращения 2021 сентябрь 13]. Режим доступа: http://minzdrav.gov.by/ru/ministerstvo/Ministry of Health of the Republic of Belarus [Electronic resource]. [date of access 2021 September 13]. Available from: http://minzdrav.gov.by/ru/ministerstvo/ (In Russ.).Республиканское унитарное предприятие «Центр экспертиз и испытаний в здравоохранении» [Электронный ресурс]. [дата обращения 2021 сентябрь 13]. Режим доступа: https://www.rceth.by/Center for Examinations and Tests in Health Service Republican Unitary Enterprise [Electronic resource]. [date of access 2021 September 13]. Available from: https://www.rceth.by/ (In Russ.)Ryzhikov AB, Ryzhikov ЕА, Bogryantseva MP, Usova SV, Danilenko ED, et al. A single blind, placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the “EpiVacCorona” Vaccine for the prevention of COVID-19, in volunteers aged 18–60 years (phase I–II). Russian Journal of Infection and Immunity. 2021;11(2):283-296. DOI: https://doi.org/10.15789/2220-7619-ASB-1699Ryzhikov AB, Ryzhikov ЕА, Bogryantseva MP, Usova SV, Danilenko ED, et al. A single blind, placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the “EpiVacCorona” Vaccine for the prevention of COVID-19, in volunteers aged 18–60 years (phase I–II). Russian Journal of Infection and Immunity. 2021;11(2):283-296. DOI: https://doi.org/10.15789/2220-7619-ASB-1699Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med. 2020 Jul;26(7):1033-1036. DOI: https://doi.org/10.1038/s41591-020-0913-5Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med. 2020 Jul;26(7):1033-1036. DOI: https://doi.org/10.1038/s41591-020-0913-5Tukhvatulin AI, Dolzhikova IV, Shcheblyakov DV, Zubkova OV, Dzharullaeva AS, et al. An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine “Sputnik Light” for prevention of coronavirus infection in healthy adults. The Lancet Regional Health – Europe. 2021 Dec;11:100241. DOI: https://doi.org/10.1016/j.lanepe.2021.100241Tukhvatulin AI, Dolzhikova IV, Shcheblyakov DV, Zubkova OV, Dzharullaeva AS, et al. An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine “Sputnik Light” for prevention of coronavirus infection in healthy adults. The Lancet Regional Health – Europe. 2021 Dec;11:100241. DOI: https://doi.org/10.1016/j.lanepe.2021.100241Basta NE, Halloran ME, Matrajt L, Longini IM Jr. Estimating influenza vaccine efficacy from challenge and community-based study data. Am J Epidemiol. 2008 Dec 15;168(12):1343-1352. DOI: https://doi.org/10.1093/aje/kwn259Basta NE, Halloran ME, Matrajt L, Longini IM Jr. Estimating influenza vaccine efficacy from challenge and community-based study data. Am J Epidemiol. 2008 Dec 15;168(12):1343-1352. DOI: https://doi.org/10.1093/aje/kwn259Bozio CH, Grannis SJ, Naleway AL, Ong TC, Butterfield KA, et al. Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19-Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 5;70(44):1539-1544. DOI: https://doi.org/10.15585/mmwr.mm7044e1Bozio CH, Grannis SJ, Naleway AL, Ong TC, Butterfield KA, et al. Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19-Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 5;70(44):1539-1544. DOI: https://doi.org/10.15585/mmwr.mm7044e1Chen J, Miao L, Li JM, Li YY, Zhu QY, Zhou CL, Fang HQ, Chen HP. Receptor-binding domain of SARS-Cov spike protein: soluble expression in E. coli, purification and functional characterization. World J Gastroenterol. 2005 Oct 21;11(39):6159-6164. DOI: https://doi.org/10.3748/wjg.v11.i39.6159Chen J, Miao L, Li JM, Li YY, Zhu QY, Zhou CL, Fang HQ, Chen HP. Receptor-binding domain of SARS-Cov spike protein: soluble expression in E. coli, purification and functional characterization. World J Gastroenterol. 2005 Oct 21;11(39):6159-6164. DOI: https://doi.org/10.3748/wjg.v11.i39.6159COVID-19 vaccine tracker and landscape [Electronic resource]. WorldHealth Organization (WHO). [date of access 2021 September 13]. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccinesCOVID-19 vaccine tracker and landscape [Electronic resource]. World Health Organization (WHO). [date of access 2021 September 13]. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccinesXu R, Shi M, Li J, Song P, Li N. Construction of SARS-CoV-2 Virus-Like Particles by Mammalian Expression System. Front Bioeng Biotechnol. 2020 Jul 30;8:862. DOI: https://doi.org/10.3389/fbioe.2020.00862Xu R, Shi M, Li J, Song P, Li N. Construction of SARS-CoV-2 Virus-Like Particles by Mammalian Expression System. Front Bioeng Biotechnol. 2020 Jul 30;8:862. DOI: https://doi.org/10.3389/fbioe.2020.00862Gavi. The Gavi COVAX AMC: an investment opportunity [Электронныйресурс]. [дата обращения 2021 сентябрь 13]. Режим доступа: https://www.gavi.org/investment-opportunity-gavi-covax-amcGavi. The Gavi COVAX AMC: an investment opportunity [Electronic resource]. [date of access 2021 September 13]. Available from: https://www.gavi.org/investment-opportunity-gavi-covax-amcHanquet G, Valenciano M, Simondon F, Moren A. Vaccine effects and impact of vaccination programmes in post-licensure studies. Vaccine. 2013 Nov 19;31(48):5634-5642. DOI: https://doi.org/10.1016/j.vaccine.2013.07.006Hanquet G, Valenciano M, Simondon F, Moren A. Vaccine effects and impact of vaccination programmes in post-licensure studies. Vaccine. 2013 Nov 19;31(48):5634-5642. DOI: https://doi.org/10.1016/j.vaccine.2013.07.006Hodgson SH, Mansatta K, Mallett G, Harris V, Emary KRW, Pollard AJ. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infect Dis. 2021 Feb;21(2):e26-e35. DOI: https://doi.org/10.1016/S1473-3099(20)30773-8Hodgson SH, Mansatta K, Mallett G, Harris V, Emary KRW, Pollard AJ. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infect Dis. 2021 Feb;21(2):e26-e35. DOI: https://doi.org/10.1016/S1473-3099(20)30773-8Рыжиков АБ, Рыжиков ЕА, Богрянцева МП, Гаврилова ЕВ, Даниленко ЕД, Иматдинов ИР, Максютов РА, Нечаева ЕА, Попова АЮ, Пьянков ОВ, Пьянкова ОГ, Суслопаров ИМ. Вакцинная композиция против коронавирусной инфекции COVID-19. [Электронный ресурс]. Патент Рос. Федерации № 2743595. 20.02.2020. [дата обращения 2021 сентябрь 13]. Режим доступа: https://new.fips.ru/registers-doc-view/fips_servlet?DB=RUPAT&DocNumber=2743595&TypeFile=htmlRyzhikov AB, Ryzhikov EA, Bogryantseva MP, Gavrilova EV, Danilenko ED, Imatdinov IR, Maksyutov RA, Nechaeva EA, Popova AY, Pyankov OV, Pyankova OG, Susloparov IM. Vaccine composition against coronavirus infection COVID-19 [Electronic resource]. Patent of Russian Federation N 2743595. 20.02.2020. [date of access 2021 September 13]. Available from: https://new.fips.ru/registers-doc-view/fips_servlet?DB=RUPAT&DocNumber=2743595&TypeFile=html (In Russ.).The Development of a COVID19 Oral Vaccine Consisting of Bacillus Subtilis Spores [Electronic resource]. ClinicalTrials.gov. [date of access 2021 September 13]. Available from: https://clinicaltrials.gov/ct2/show/record/NCT05057923The Development of a COVID19 Oral Vaccine Consisting of Bacillus Subtilis Spores [Electronic resource]. ClinicalTrials.gov. [date of access 2021 September 13]. Available from: https://clinicaltrials.gov/ct2/show/record/NCT05057923Understanding Viral Vector COVID-19 Vaccines. [Electronic resource]. Centers for Disease Control and Prevention [date of access 2021 September 13]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/viralvector.htmlUnderstanding Viral Vector COVID-19 Vaccines. [Electronic resource]. Centers for Disease Control and Prevention [date of access 2021 September 13]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/viralvector.htmlKrammer, F. SARS-CoV-2 vaccines in development. Nature 2020 Oct;586(7830):516-5276. DOI: https://doi.org/10.1038/s41586-020-2798-3Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020 Oct;586(7830):516-5276. DOI: https://doi.org/10.1038/s41586-020-2798-3Rattanapisit K, Shanmugaraj B, Manopwisedjaroen S, Purwono PB, Siriwattananon K, et al. Rapid production of SARS-CoV-2 receptor binding domain (RBD) and spike specific monoclonal antibody CR3022 in Nicotianabenthamiana. Sci Rep. 2020 Oct 19;10(1):17698. DOI: https://doi.org/10.1038/s41598-020-74904-1Rattanapisit K, Shanmugaraj B, Manopwisedjaroen S, Purwono PB, Siriwattananon K, et al. Rapid production of SARS-CoV-2 receptor binding domain (RBD) and spike specific monoclonal antibody CR3022 in Nicotiana benthamiana. Sci Rep. 2020 Oct 19;10(1):17698. DOI: https://doi.org/10.1038/s41598-020-74904-1Thanh Le T, Andreadakis Z, Kumar A, Gómez Román R, Tollefsen S, Saville M, Mayhew S. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020 May;19(5):305-306. DOI: https://doi.org/10.1038/d41573-020-00073-5Thanh Le T, Andreadakis Z, Kumar A, Gómez Román R, Tollefsen S, Saville M, Mayhew S. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020 May;19(5):305-306. DOI: https://doi.org/10.1038/d41573-020-00073-5Velázquez RF, Linhares AC, Muñoz S, Seron P, Lorca P, DeAntonio R, Ortega-Barria E. Efficacy, safety and effectiveness of licensed rotavirus vaccines: a systematic review and meta-analysis for Latin America and the Caribbean. BMC Pediatr. 2017 Jan 13;17(1):14. DOI: https://doi.org/10.1186/s12887-016-0771-yVelázquez RF, Linhares AC, Muñoz S, Seron P, Lorca P, DeAntonio R, Ortega-Barria E. Efficacy, safety and effectiveness of licensed rotavirus vaccines: a systematic review and meta-analysis for Latin America and the Caribbean. BMC Pediatr. 2017 Jan 13;17(1):14. DOI: https://doi.org/10.1186/s12887-016-0771-yWang H, Zhang Y, Huang B, Deng W, Quan Y, et al. Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2. Cell. 2020 Aug 6;182(3):713-721.e9. DOI: https://doi.org/10.1016/j.cell.2020.06.008Wang H, Zhang Y, Huang B, Deng W, Quan Y, et al. Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2. Cell. 2020 Aug 6;182(3):713-721.e9. DOI: https://doi.org/10.1016/j.cell.2020.06.008Weinberg GA, Szilagyi PG. Vaccine epidemiology: efficacy, effectiveness, and the translational research roadmap. J Infect Dis. 2010 Jun 1;201(11):1607-1610. DOI: https://doi.org/10.1086/652404Weinberg GA, Szilagyi PG. Vaccine epidemiology: efficacy, effectiveness, and the translational research roadmap. J Infect Dis. 2010 Jun 1;201(11):1607-1610. DOI: https://doi.org/10.1086/652404WHO Target Product Profiles for COVID-19 Vaccines. [Электронный ресурс]. World Health Organization (WHO). [дата обращения 2021 сентябрь 13]. Режим доступа: https://www.who.int/publications/m/item/who-target-product-profiles-for-covid-19-vaccinesWHO Target Product Profiles for COVID-19 Vaccines. [Electronic resource].World Health Organization (WHO). [date of access 2021 September 13]. Available from: https://www.who.int/publications/m/item/who-target-product-profiles-for-covid-19-vaccinesWorld Health Organization (WHO) [Electronic resource]. [date of access 2021 September 13]. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccinesWorld Health Organization (WHO) [Electronic resource]. [date of access 2021 September 13]. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccinesZhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020 Aug 15;396(10249):479-488. DOI: https://doi.org/10.1016/S0140-6736(20)31605-6Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, doubleblind, placebo-controlled, phase 2 trial. Lancet. 2020 Aug 15;396(10249):479-488. DOI: https://doi.org/10.1016/S0140-6736(20)31605-6

The authors declare that there are no conflicts of interest present.